Monika Gullerova

Monika Gullerova is a Professor of Molecular Medicine at the University of Oxford, a Principal Investigator in the Sir William Dunn School of Pathology, a Medical Tutor at Wadham College, and a Senior Research Fellow at Cancer Research UK. Her research group focuses on AI-driven RNA-targeted drug discovery. She leads the Raiden Project, developing a multimodal deep-learning platform for drug screening that integrates graph neural networks with RNA sequence and three-dimensional structural information to enable large-scale AI virtual screening of RNA–small-molecule interactions. The group has established a closed-loop discovery model combining AI-based computational design, wet-lab experimental validation, and iterative model refinement using experimental data. This approach aims to develop small-molecule therapies against non-coding RNA cancer targets that have traditionally been considered difficult to drug, while overcoming the delivery and stability limitations of oligonucleotide therapeutics. Building on the Raiden Project’s technological advances, she co-founded Raiden Therapeutics, an Oxford spin-out AI biotechnology company, to advance innovative preclinical pipelines. Her group also conducts fundamental RNA biology research, including studies of how non-coding RNAs regulate DNA damage repair. She was selected for the MIT–Royalty Pharma global university entrepreneurship program and received the L’Oréal–UNESCO For Women in Science Award. She is committed to translating AI-enabled life-science research into real-world applications and promoting interdisciplinary innovation at the intersection of computer science, artificial intelligence, and molecular medicine.